

## Special Issue

# Lipid Metabolism: Functions, Biomarkers and Therapies

### Message from the Guest Editors

We are pleased to announce our support and editorial responsibility for a new Special Issue of *Biomedicines*, entitled “MicroRNAs in Lipid Metabolism: Functions, Biomarkers and Therapies”. MicroRNAs (miRNAs) are a family of important transcriptional and post-transcriptional regulators of the target genes that codify the proteins that are involved in multiple lipid metabolism pathways, thereby influencing cholesterol and fatty acid homeostasis. These miRNAs have emerged as promising therapeutic targets for the treatment of lipid-related metabolic alterations in diseases such as atherosclerosis, diabetes, obesity, and liver disease. Most of these miRNAs act at an intracellular level, but they can be also transported in biofluids and used as potential biomarkers of lipid metabolic alterations. This Special Issue aims to publish timely and informative findings on miRNAs and their influence on lipid and lipoprotein metabolism. Original research articles and reviews are welcome. Dr. Josep Julve

### Guest Editors

Dr. Joan Carles Escolà-Gil

Institut d'Investigacions Biomèdiques (IIB) Sant Pau, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain

Dr. Noemí Rotllan

Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain

### Deadline for manuscript submissions

closed (31 March 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/109928](https://mdpi.com/si/109928)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).